All In MedTech

Device Trial Radar · NCT04534660

Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler

A Feasibility Study to Evaluate Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler

Last checked: Nov 20, 2026Latest source record: May 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Nov 10, 2020

Primary completion

Aug 24, 2021

Study completion Jun 23, 2023

Sponsor

Lead sponsor
Sofregen Medical, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Symbio, LLC
First posted
Sep 1, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter (two clinical sites), unblinded, no control group, prospective feasibility study. Subject participation may last up to 24 months after enrollment. Treatment will be performed at Day 1 and optionally at Day 30, with the primary safety and effectiveness evaluation at 2 months. Subjects will continue extended follow-up evaluations at 4, 6, 12, 18 and 24 months after the final injection. The duration and follow-up schedule will be identical, independent of treatment performed.

Conditions

  • Nasolabial Fold
  • Cheek Augmentation

Interventions

  • SMI-01Device

    SMI-01 is a device consisting of silk particles in a hydrogel carrier.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To obtain clinician feedback on overall ease of use of device on a scale of 0 -10 (0 being not easy and 10 being most easy)Time frame: Initial Treatment, Day 1
  2. Patient reported incidence of CTR's and any treatment emergent adverse eventsTime frame: Day 30
  3. Patient reported severity (mild, moderate or severe) of CTR's and any treatment emergent adverse eventsTime frame: Day 30

6 more outcomes with a free account

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • California Dermatology & Clinical Research Institute

    Encinitas, California

  • Baumann Cosmetic & Research Institute

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.